To amend the Federal Food, Drug, and Cosmetic Act to authorize priority review for breakthrough devices.

To amend the Federal Food, Drug, and Cosmetic Act to authorize priority review for breakthrough devices. 1. Priority review for breakthrough devices (a) In general Chapter V of the Federal Food, Drug, and Cosmetic Act is amended— (1) in section 515(d)— (A) by striking paragraph (5); and (B) by redesignating paragraph (6) as paragraph (5); and (2) by inserting after section 515A ( 21 U.S.C. 360e–1 515B. Priority review for breakthrough devices (a) In general In order to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions, the Secretary shall establish (1) representing breakthrough technologies; (2) for which no approved alternatives exist; (3) offering significant advantages over existing approved or cleared alternatives, including the potential to, compared to existing approved or cleared alternatives, reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients’ ability to manage their own care (such as through self-directed personal assistance), or establish long-term clinical efficiencies; or (4) the availability of which is in the best interest of patients. (b) Request for designation A sponsor of a device may request that the Secretary designate the device for priority review under this section. Any such request for designation may be made at any time prior to the submission of an application under section 515(c), a petition for classification under section 513(f)(2), or a notification under section 510(k). (c) Designation process (1) In general Not later than 60 calendar days after the receipt of a request under subsection (b), the Secretary shall determine whether the device that is the subject of the request meets the criteria described in subsection (a). If the Secretary determines that the device meets the criteria, the Secretary shall designate the device for priority review. (2) Review Review of a request under subsection (b) shall be undertaken by a team that is composed of experienced staff and managers of the Food and Drug Administration and is chaired by a senior manager. (3) Designation determination A determination approving or denying a request under subsection (b) shall be considered a significant decision under section 517A and the Secretary shall provide a written, substantive summary of the basis for the determination in accordance with section 517A(a). (4) Reconsideration (A) Request for reconsideration Any person whose request under subsection (b) is denied may, within 30 days of the denial, request reconsideration of the denial in accordance with section 517A(b)— (i) based upon the submission of documents by such person; or (ii) based upon such documents and a meeting or teleconference. (B) Response Reconsideration of a designation determination under this paragraph shall be conducted in accordance with section 517A(b). (5) Withdrawal If the Secretary approves a priority review designation for a device under this section, the Secretary may not withdraw the designation based on the fact that the criteria specified in subsection (a) are no longer met because of the subsequent clearance or approval of another device that was designated under— (A) this section; or (B) section 515(d)(5) (as in effect immediately prior to the enactment of the 21st Century Cures Act). (d) Priority review (1) Actions For purposes of expediting the development and review of devices designated under subsection (c), the Secretary shall— (A) assign a team of staff, including a team leader with appropriate subject matter expertise and experience, for each device for which a request is submitted under subsection (b); (B) provide for oversight of the team by senior agency personnel to facilitate the efficient development of the device and the efficient review of any submission described in subsection (b) for the device; (C) adopt an efficient process for timely dispute resolution; (D) provide for interactive communication with the sponsor of the device during the review process; (E) expedite the Secretary’s review of manufacturing and quality systems compliance, as applicable; (F) disclose to the sponsor in advance the topics of any consultation concerning the sponsor’s device that the Secretary intends to undertake with external experts or an advisory committee and provide the sponsor an opportunity to recommend such external experts; (G) for applications submitted under section 515(c), provide for advisory committee input, as the Secretary determines appropriate (including in response to the request of the sponsor); and (H) assign staff to be available within a reasonable time to address questions by institutional review committees concerning the conditions and clinical testing requirements applicable to the investigational use of the device pursuant to an exemption under section 520(g). (2) Additional actions In addition to the actions described in paragraph (1), for purposes of expediting the development and review of devices designated under subsection (c), the Secretary, in collaboration with the device sponsor, may, as appropriate— (A) coordinate with the sponsor regarding early agreement on a data development plan; (B) take steps to ensure that the design of clinical trials is as efficient as practicable, such as through adoption of shorter or smaller clinical trials, application of surrogate end­points, and use of adaptive trial designs and Bayesian statistics, to the extent scientifically appropriate; (C) facilitate, to the extent scientifically appropriate, expedited and efficient development and review of the device through utilization of timely postmarket data collection, with regard to applications for approval under section 515(c); and (D) agree to clinical protocols that the Secretary will consider binding on the Secretary and the sponsor, subject to— (i) changes agreed to by the sponsor and the Secretary; (ii) changes that the Secretary determines are required to prevent an unreasonable risk to the public health; or (iii) the identification of a substantial scientific issue determined by the Secretary to be essential to the safety or effectiveness of the device involved. (e) Priority review guidance (1) Content The Secretary shall issue guidance on the implementation of this section. Such guidance shall include the following: (A) The process for a person to seek a priority review designation. (B) A template for requests under subsection (b). (C) The criteria the Secretary will use in evaluating a request for priority review. (D) The standards the Secretary will use in assigning a team of staff, including team leaders, to review devices designated for priority review, including any training required for such personnel on effective and efficient review. (2) Process Prior to finalizing the guidance under paragraph (1), the Secretary shall propose such guidance for public comment. (f) Construction (1) Purpose This section is intended to encourage the Secretary and provide the Secretary sufficient authorities to apply efficient and flexible approaches to expedite the development of, and prioritize the agency’s review of, devices that represent breakthrough technologies. (2) Construction . (b) Conforming amendment related to designation determinations Section 517A(a)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360g–1(a)(1) a request for designation under section 515B, an application under section 515,

Summary: This bill amends the Federal Food, Drug, and Cosmetic Act to replace the requirement that the Food and Drug Administration (FDA) prioritize review of breakthrough medical devices with a requirement that the FDA establish a program to provide priority review for breakthrough medical devices. Prior to submitting an application for approval, a medical device sponsor may request that the FDA designate the medical device for priority review. The FDA must provide a summary of the basis for its determination regarding designation. To expedite the development and review of designated medical devices, the FDA must: assign a team of staff for each device, adopt an efficient process for dispute resolution, provide for interactive communication with the device sponsor, expedite review of manufacturing and quality systems compliance, disclose to the sponsor in advance the topics of any consultation between the FDA and external experts or an advisory committee and provide the sponsor the opportunity to recommend external experts, assign staff to address questions by institutional review committees concerning investigational use of the device. The FDA may: (1) coordinate with the sponsor regarding early agreement on a data development plan; (2) take steps to ensure that the design of clinical trials is as efficient as practicable; (3) utilize timely postmarket data collection; and (4) agree to clinical protocols, subject to an FDA determination that changes are required to prevent an unreasonable risk to the public health or that a substantial scientific issue is essential to the safety or effectiveness of the device.